A NEW MEDICINE PUBLICATION VOLUME 6, NUMBER 1-12 INDEX JUNE 2002

COPYRIGHT © 2002 NEW MEDICINE INC. UNAUTHORIZED PHOTOCOPYING, DISTRIBUTION OR ELECTRONIC STORAGE IS PROHIBITED BY LAW.

BLADDER CANCER — PART IISCREENING, DIAGNOSIS, STAGING

AND FOLLOW-UP

SCREENING 1250

DIAGNOSIS AND FOLLOW-UP 1253

In Vitro Testing Approaches 1253

Urine cytology/cytopathology 1255

ImmunoCyt 1255

Quanticyt 1255

Bladder tumor antigen (BTA) 1256

Nuclear matrix proteins (NMP) 1258

NMP-22 1258

BCLA-4 1260

Fibrin/fibrinogen degradation products (FDP) 1261

Telomerase 1261

p53 mutations and other genetic markers 1262

Cytokeratin (CK) 1264

Hyaluronic acid (HA) and hyaluronidase (HAase) 1266

Cystoscopy/Biopsy 1266

HISTOPATHOLOGY AND

BLADDER CANCER TYPES 1267

Transitional Cell Carcinoma (TCC) 1267

Squamous Cell Carcinoma 1267

Adenocarcinoma 1267

STAGE AND GRADE 1267

BLADDER CANCER — PART IIITREATMENT APPROACHES IN

CURRENT PRACTICE AND IN EVALUATION

SURGERY 1322

Transurethral Resection (TUR) 1322

Partial (Segmented) Cystectomy 1323

Radical Cystectomy 1323

Bladder reconstruction surgery 1323

RADIOTHERAPY (RT) 1324

Radiosensitization 1325

Brachytherapy 1325

CHEMOTHERAPY 1326

Systemic Chemotherapy 1326

Platinum-based chemotherapy 1326

Other combination regimens 1333

Intravesical Chemotherapy 1333

IMMUNOTHERAPY 1335

Intravesical Immunotherapy 1335

Bacillus Calmette-Guérin (BCG) 1336

Interferon α (IFN-α) 1337

Interleukin-2 (IL-2) 1337

Systemic Immunotherapy 1337

PHOTODYNAMIC THERAPY (PDT) 1338

HYPERTHERMIA 1339

MULTIMODALITY THERAPY 1339

BLADDER CANCER — PART IVPROGNOSIS AND TREATMENT

OF BLADDER CANCER BY STAGE AND GRADE

TREATMENT OF BLADDER CANCER 1350

Superficial Bladder Cancer 1350

Low-risk superficial bladder cancer 1352

High-risk superficial bladder cancer 1352

Carcinoma in situ (CIS) 1356

Muscle-invasive Disease 1356

Recurrent Disease 1356

Upper Urinary Tract TCC 1357

Metastatic Bladder Cancer 1357

PROGNOSTIC AND PREDICTIVE FACTORS

AND DISEASE MONITORING 1357

Surveillance Requirements 1358

Clinical Factors 1358

Chromosomal Abnormalities 1358

Molecular Markers 1359

p53 1359

Cell-cycle regulators 1363

Cell-adhesion factors 1364

BLADDER CANCER — PART VNOVEL THERAPEUTICS IN DEVELOPMENT

SYSTEMIC CYTOTOXIC CHEMOTHERAPY 1386

Alimta 1386

Arsenic Trioxide 1386

CAI 1386

CS-682 1387

Eflornithine 1387

Etanidazole 1388

Fenretinide 1388

Halofuginone 1389

J-107088 1389

ZD0473 1389

INTRAVESICAL CYTOTOXIC

CHEMOTHERAPY 1389

Amrubicin 1389

Meglumine-GLA (MeGLA) 1390

SYSTEMIC IMMUNOTHERAPY 1391

Bropirimine 1391

MAGE-3 Protein Vaccine 1392

Monocyte-derived Activated Killer (MAK) Cell Technology 1393

Phosphodiester Oligonucleotides as Immunomodulators 1393

INTRAVESICAL IMMUNOTHERAPY 1393

BCI-ImmuneActivator (BCI-IA) 1393

Interleukin-12 (IL-12) 1399

Mycobacterium Cell-Wall Complex (MCC) 1399

REGULATORY AGENTS 1400

Exisulind 1400

Proteasome Inhibitor LDP-341 1400

R115777 1400

Thalidomide 1401

ZD1839 1401

GENE TRANSFER/THERAPY 1401

CV876 1401

INGN-201 1401

SCH-58500 1402

OTHER APPROACHES 1402

Intravesical Radioimmunotherapy 1402

Photodynamic Therapy (PDT) 1402

Hexvix 1402

T A B L E O F C O N T E N T S

STATE-OF-THE-ART INTHE MANAGEMENT OF CANCER

2

FUTURE ONCOLOGY VOLUME 6, NUMBER 1-12 INDEX JUNE 2002

COPYRIGHT © 2002 NEW MEDICINE INC. 949. 830. 0448.

TECHNOLOGY UPDATESYNTHETIC NUCLEIC

ACID SEQUENCE CONSTRUCTS AS ONCOLOGY

THERAPEUTICS — PART II

TYPES OF SYNTHETIC NUCLEIC ACID

CONSTRUCTS IN DEVELOPMENT AS

ONCOLOGY THERAPEUTICS 1269

Antisense Oligos 1269

Triplex-Forming ODN (TFO) 1269

Catalytic Nucleic Acids/Ribozymes 1270

Hammerhead ribozymes 1271

Minizyme 1271

Maxizymes 1271

Hairpin ribozymes 1271

Snorbozymes 1272

Deoxyribozymes or DNA enzymes (DNAzymes) 1272

Dy-Tex ribozyme analogs 1272

Chimeric Nucleotides 1272

Intracellularly Produced Antisense RNA and DNA 1273

Aptamers 1274

Aptazymes 1275

Aptamers as diagnostics 1276

BIOLOGICAL ACTIVITY OF ODN 1276

CpG-containing ODN 1276

G-rich ODN 1277

ODN Conjugated to Radioisotopes 1278

CLINICAL CONSIDERATIONS 1278

Toxicity 1278

Administration Route 1278

Oral delivery 1278

Pulmonary delivery 1279

Combination Therapy 1279

SYNTHETIC NUCLEIC ACID SEQUENCE CONSTRUCTS AS

ONCOLOGYTHERAPEUTICS — PART III

MOLECULAR TARGETS IN ONCOLOGY 1282

C-myc 1282

Oncomyc-NG (AVI-4126) 1284

INX-3280 1284

C-myb 1285

INX-3001 1285

Raf 1285

ISIS 5132 1286

LE-AON 1287

Ras 1287

ISIS 2503 1287

Protein Kinases 1289

ISIS 3521 1289

GEM 231 1298

Bcl-2 1299

Genasense (G3139) 1300

Vascular Endothelial Growth Factor (VEGF) 1305

Angiozyme 1305

DNA-MeTase (DNA Methyltransferase) 1305

MG98 1305

Ribonucleotide reductase (RNR) 1306

GTI 2040 1306

Insulin-like Growth Factor (IGF)-I -II and IGF-Ir 1307

OTHER POTENTIAL SNAS INTERVENTIONS IN ONCOLOGY 1307

Oncogene Inhibition 1307

Oncogene bcr-abl 1307

Murine double-minute 2 (mdm2) 1308

Modulation of Tumor Suppressor Genes 1309

BRCA1 1309

Modulation of Signal Tranduction Pathways 1309

Epidermal growth factor (EGF) and transforming growth factor (TGF)-α 1309

Prevention of Metastasis 1310

The α V integrins 1310

Focal adhesion kinase (FAK) 1310

Enhancement of Apoptosis 1311

Inhibitors of apoptosis proteins (IAP) 1311

Telomerase Inhibition 1311

Modulation of Chemotherapeutics 1311

Immunotherapy 1312

Viral Inhibition 1312

DIAGNOSTIC, RESEARCH AND DRUG

DISCOVERY APPLICATIONS 1313

DEVELOPERS OF SNAS-BASED

ONCOLOGY DRUGS 1313

atugen 1313

AVI BioPharma 1314

Coley Pharmaceutical Group 1314

Cytoclonal Pharmaceutics 1315

EpiGenesis Pharmaceuticals 1315

Gemini Technologies 1315

Genta 1315

Hybridon 1316

Immusol 1316

Inex Pharmaceuticals 1317

Isis Pharmaceuticals 1317

Lorus Therapeutics 1317

MethylGene 1318

Ribozyme Pharmaceuticals (RPI) 1318

GLOBAL MARKETS OFANTICANCER DRUGS AND

ADJUNCTS

CYTOTOXICS 1403

HORMONE MODULATORS 1403

ANTICANCER BIOLOGICALS 1403

REGULATORY AGENTS 1404

ADJUNCTS 1404

Biologicals 1404

Antiemetics 1404

Hypercalcemia and Bone Metastasis-related Treatments 1404

OTHERS 1404

MEDICARE REIMBURSEMENT OF ONCOLOGY DRUGS

UPDATE ON SPINDLE POISONS — PART I

TAXANES, GENERIC PACLITAXEL,AND NOVEL

FORMULATIONS AND ANALOGS

CURRENT MARKETS FOR

COMMERCIALLY AVAILABLE TAXANES 1422

MECHANISM OF ACTION OF TAXANES

AND SPINDLE POISONS 1422

Mechanism of Action of Taxanes 1422

Drug Resistance 1423

Cyclosporin A (CsA) and its analogs/derivatives 1426

GF120918 1427

ONT-093 1428

R101933 1428

tRA96023 1428

VX-710 1429

XR9576 1429

Chemosensitization 1429

AVI-4557 1429

TECHNOLOGY UPDATE

ONCOLOGY TRENDS

ANTICANCER DRUGS AND MARKETS

3

Toxicity 1434

BNP7787 1434

Prosaptide 1435

APPROVED AND/OR COMMERCIALLY

AVAILABLE TAXANES 1435

Paclitaxel 1436

Taxol 1436

Paxene 1436

Docetaxel 1436

Taxotere 1436

TAXANE SOURCES, PRODUCTION

PROCESSES, AND GENERIC PACLITAXEL 1436

Abbott Laboratories 1440

Aphios 1440

Biolyse Pharma 1440

Dabur India 1440

eXegenics 1440

Faulding 1440

Indena 1440

Ivax 1440

Mylan Pharmaceuticals 1441

NaPro BioTherapeutics 1441

Natural Pharmaceuticals 1441

Phytogen Life Sciences 1441

Phyton 1441

Samyang Genex 1442

Xechem International 1442

NOVEL FORMULATIONS 1442

ABI-007 1442

CT-2103 (PG-TXL) 1443

Fibrinogen-Coated EmulsionFormulation of Docetaxel 1445

Genetaxyl 1445

Liposome-encapsulated paclitaxel (LEP) 1445

OncoGel 1446

Paclimer Microspheres 1447

PacoExtra 1447

Paxoral 1447

PEG-paclitaxel 1448

S-8184 1448

SP5.210C 1449

Taxoprexin 1449

Taxosomes/Dermos 1450

NOVEL TAXANES AND ANALOGS 1450

BAY 59-8862 (IDN5109) 1450

BMS-184476 1451

BMS-188797 1451

BMS-275183 1452

DJ-927 1452

RPR109881 1453

RPR116258A 1453

TL-139 1454

Tumor-activated Prodrug (TAP)-Taxane Immunoconjugates 1454

TXD258 (TAX 258) 1455

NOVEL SPINDLE POISONS 1455

UPDATE ON SPINDLE POISONS — PART II

VINCA ALKALOIDS AND ANALOGS/FORMULATIONS

MECHANISM OF ACTION OF

VINCA ALKALOIDS 1457

COMMERICALLY AVAILABLE

VINCA ALKALOIDS 1458

Vinblastine 1458

Vincristine 1459

Vindesine 1459

Vinorelbine 1459

Oral vinorelbine 1459

APPLICATIONS OF VINCA ALKALOIDS

IN DEVELOPMENT 1460

Breast Cancer 1460

Lung Cancer 1461

Bladder Cancer 1470

Other Cancers 1471

NOVEL VINCA ALKALOID ANALOGS

AND FORMULATIONS 1472

Anhydrovinblastine (AVLB) 1472

Liposomal Formulations of Vinblastine and Vinorelbine 1473

Vincristine Sulfate Liposome Injection (VSLI) 1473

Vinflunine 1475

GENE THERAPY OF CANCER — PART I

GENE TRANSFER STRATEGIES

FROM THE 9TH INTERNATIONAL CONFERENCE

ON GENE THERAPY OF CANCER, SPONSORED BY SIDNEY KIMMEL CANCER

CENTER, IN SAN DIEGO, CA, ON DECEMBER 7-9, 2000

VIRAL VECTORS 1341

Adenovirus 1341

Introgen Therapeutics 1342

Cell Genesys 1342

Canji 1342

Genphar 1342

Onyx Pharmaceuticals 1342

St. Louis University School of Medicine 1343

Yale University School of Medicine 1343

University of Arizona 1344

Ontario Cancer Institute 1344

GenVec 1344

Adeno-associated Virus (AAV) 1344

Retrovirus 1344

Vanderbilt University Medical Center 1344

King’s College London 1345

Lentivirus 1345

Herpes Simplex Virus (HSV) 1345

University of Calgary 1345

Live Poxvirus 1345

Loma Linda University School of Medicine 1345

Thomas Jefferson University 1345

Pseudovirion 1345

NONVIRAL GENE TRANSFER 1345

Polycationic Polymers 1346

Baylor College of Medicine 1346

Valentis 1346

Supratek Pharma 1346

Cationic Lipids 1346

Vical 1346

Genzyme Molecular Oncology 1346

Peptide Conjugates 1346

Shinshu University School of Medicine 1347

Filamentous Bacteriophage 1347

Selective Genetics 1347

Liposomal Vesicles 1347

Teikyo University School of Medicine 1347

Immunoprotective Microcapsules 1347

University of Bergen 1347

Combined Nonviral and Viral GeneDelivery 1347

Genetic Therapy 1347

GENE THERAPY OF CANCER — PART II

MECHANISM-BASED AND OTHER TREATMENT

OPTIONS FROM THE 9TH INTERNATIONAL

CONFERENCE ON GENE THERAPY OF CANCER, SPONSORED BY SIDNEY KIMMEL CANCER

CENTER, SAN DIEGO, CA, DECEMBER 7-9, 2000

FUTURE ONCOLOGY VOLUME 6, NUMBER 1-12 INDEX JUNE 2002

COPYRIGHT © 2002 NEW MEDICINE INC. 949. 830. 0448.

MEETING COVERAGE

TUMOR SUPPRESSOR

COMPENSATION/ENHANCEMENT/TARGETING 1364

p53 1365

Replacement of a defective p53 gene 1365

Cytolytic agents targeting p53-deficient cancer cells 1366

mda-7 1366

pHyde 1367

p27 1367

INHIBITION/KNOCK-OUT OF PROMOTERS

OF TUMOR GROWTH 1368

Sex hormone-binding globulin (SHBG) 1368

T-ag of Human Polyomavirus BK (BKV) 1368

K-ras 1368

GROWTH FACTOR SUPPRESSION 1369

Transforming growth factors (TGF) 1369

ANTIANGIOGENIC GENE THERAPY 1369

In vivo Delivery and Expression ofEndostatin 1370

Tumor Suppressor Activity andInhibition of Angiogenesis 1371

SUICIDE GENE-BASED APPROACHES 1371

Gene-directed Enzyme Prodrug Therapy (GDEPT) 1371

HSVtk/ganciclovir 1371

Cytosine deaminase/5-fluorocytosine (CD/5-FC) 1372

Cytochrome P450/cyclophosphamide (CYP/CP) 1373

Horseradish peroxidase/indole-3-acetic acid (HRP/IAA) 1374

Carboxylesterase/irinotecan (CE/CPT-11) 1374

Methioninase/selenomethionine (METase/SeMET) 1375

Beta-glucuronidase/HMR 1826 1376

Self-Deleting Vectors 1376

OTHER DIRECT CYTOTOXICITY

APPROACHES 1377

Transfer of Genes Encoding Viral Fusogenic MembraneGlycoproteins 1377

Tumor-specific Activation of dsRNA-dependent PKR 1377

Attenuated, Replication-competent Adenoviruses 1377

POTENTIATION OF CONVENTIONAL

THERAPY 1378

Chemotherapy Sensitization 1378

Radiation Therapy Sensitization 1380

Combined Chemo/RadiotherapySensitization 1382

Protection of Critical Host Tissues 1382

CELL MARKING STUDIES 1383

GENE THERAPY OF CANCER —PART II

IMMUNOLOGIC STIMULATION

FROM THE 9TH INTERNATIONAL CONFERENCE

ON GENE THERAPY OF CANCER, SPONSORED BY SIDNEY KIMMEL CANCER

CENTER, SAN DIEGO, CA, DECEMBER 7-9, 2000

GENETICALLY ENGINEERED

ANTIGEN PRESENTING CELLS 1406

Malignant Melanoma Immunotherapy 1406

Prostate Cancer Immunotherapy 1406

Minigene Vaccine for Solid Tumors 1407

Endogenous Production of Cytokines 1407

GENETICALLY ENGINEERED

TUMOR CELLS 1408

University of California San Diego 1408

Genzyme Molecular Oncology 1408

Supratek Pharma 1408

Osaka City University Medical School 1408

Pennsylvania State University College of Medicine 1409

Vical 1409

Valentis 1409

Loma Linda University School of Medicine 1414

King’s College London 1414

Canji 1414

Transgene 1415

Cell Genesys 1415Thomas Jefferson University 1417

VA Medical Center-Long Beach 1418

Genphar 1418

Chiba Cancer Center Research Institute 1418

REFLECTIONS FROM THE MEETINGS

OF THE AMERICAN ASSOCIATION FOR

CANCER RESEARCH (AACR), APRIL 5-10, 2002, SAN FRANCISCO, CAAND THE AMERICAN SOCIETY OF CLINICAL

ONCOLOGY (ASCO), MAY 18-21, 2002, ORLANDO FL

NOVEL AGENTS IN EARLY-STAGE

CLINICAL DEVELOPMENT 1477

MODULATION OF SIGNALING PATHWAYS 1477

INHIBITION OF ANGIOGENESIS, LYMPHOANGIOGENESIS AND

DESTRUCTION OF EXISTING

TUMOR VASCULATURE 1477

CHEMOPREVENTION 1477

EVIDENCE-BASED PRACTICE 1477

4

FUTURE ONCOLOGY VOLUME 6, NUMBER 1-12 INDEX JUNE 2002

COPYRIGHT © 2002 NEW MEDICINE INC. 949. 830. 0448.

5

FUTURE ONCOLOGY VOLUME 6, NUMBER 1-12 INDEX JUNE 2002

COPYRIGHT © 2002 NEW MEDICINE INC. 949. 830. 0448.

TITLE PAGE

In Vitro Tests for the Screening, Diagnosis, and Monitoring of Bladder Cancer 1251

Comparison of BTA Stat and Cytology in Bladder Cancer Monitoring 1258

Comparisons of UBC, BTA and NMP-22 Tests 1268

Incidence of Bladder Cancer by Histologic Type in the USA in 2000 1271

Basis for Staging of Bladder Cancer 1273

Incidence of Bladder Cancer by Stage in the USA in 2000 1275

Incidence of Bladder Cancer by Grade in the USA in 2000 1277

Combination Cancer Therapies Involving SNAS 1283

Selected Syntheic Nucleic Acid Sequence (SNAS) Constructs in Oncology 1290

TITLE PAGE

Selected Chemotherapy and Multimodality Regimens Under Evaluation in the Treatment of Bladder Cancer 1327

Estimated Incidence and Prevalence of Bladder Cancer by Stage in the USA in 2000 1351

Treatment of Bladder Cancer by Stage and Grade 1353

Clinical Prognostic and Predictive Factors 1361

Novel Agents in Development for the Treatment of Bladder Cancer 1394

Worldwide Markets of Selected Anticancer Agents and Adjuncts in 1997 and 2000 1404

Worldwide Markets of Selected Anticancer Agents in 1997 and 2000 1410

Worldwide Markets of Selected Agents Used as Oncology Adjuncts in 1997 and 2000 1416

TITLE PAGE

Worldwide Sales of Taxanes in 1999 and 2000 1423

Estimated Worldwide Quarterly Sales of Taxanes in 2001 1425

Estimated Quarterly USA Sales of Taxanes in 2001 1427

Selected Regulatory Agents Being Clinically Evaluated in Combination with Commercially Available Taxanes 1430

Novel Taxane Analogs and Formulations 1437

Results from Selected Phase II Clinical Trials of Combination/Multimodality Regimens Incorporating Vinca Alkaloids 1463

Meetings of the American Association of Cancer Research (AACR) and theAmerican Society of Clinical Oncology (ASCO) 1478

L I S T O F E X H I B I T S

Aarhus University Hospital(Denmark) 1331

Abbott Laboratories1317, 1397, 1413, 1416,

1433, 1437, 1438, 1440, 1441, 1478

Abgenix 1396, 1430

Access Oncology 1473, 1482

Access Pharmaceuticals 1478

Addenbrookes NHS Trust 1264

ADL (Germany) 1259

Aegera Therapeutics 1290

AIDS Malignancy Consortium 1431

AlbaPharm 1478

Albert Einstein College of Medicine 1272, 1299

Alcoa 1253

Alfa Wassermann 1411, 1413

Alkermes 1284, 1290

Alliance Pharmaceutical 1395

Allos Therapeutics 1430

Alza 1411, 1417, 1431

Ambion 1252, 1363

American BioScience (ABI)1437, 1439, 1442, 1443, 1454

American Home Products 1411

American Pharmaceutical Partners 1443

Amgen 1370, 1404, 1416

Angiogene Pharmaceuticals 1478

AnorMED 1389, 1394

Anthra Pharmaceuticals 1334, 1335

AntiCancer 1375, 1376, 1383

Aphios 1437, 1440, 1450

Aquila Biopharmaceuticals 1392

Arizona Cancer Center1409, 1433,1475

Arnaldo Vieira de Carvalho Cancer Institute (Brazil) 1467

Aronex Pharmaceuticals 1394

Arthur G. James Cancer Hospital 1304

Asahi Chemical Industry 1479

Asklepios Fachkliniken Muenchen-Gauting (Germany) 1467

Asta Medica 1333, 1376, 1412, 1435

AstraZeneca 1290, 1312, 1317, 1394, 1410, 1412, 1430, 1478

Atlantic Technology Ventures 1315

atugen 1313, 1315

Avecia LifeScience Molecules 1291, 1313, 1315

Avecia 1395, 1432

Aventis Pasteur 1337

Aventis Pharma1430, 1431, 1432, 1453, 1454

Aventis Pharmaceuticals 1290, 1293, 1299, 1310, 1317, 1436, 1437

Aventis 1326, 1370, 1374, 1376,1387, 1395, 1402, 1410, 1416

AVI BioPharma 1284, 1290, 1291, 1312, 1314, 1429

Axcan Pharma 1338, 1411

Axys Pharmaceuticals 1313

Azlenda Ospedaliera di Padova (Italy) 1469

Banyu 1389, 1394

Barbara Ann Karmanos Cancer Institute 1324

Bard Diagnostic Sciences 1257

Barr Laboratories 1412

BattellePharma 1478

Baxter Oncology 1430, 1435

Bayer 1252, 1437, 1450, 1478

Baylor College of Medicine 1253, 1274, 1346, 1366, 1381, 1395, 1396

Baylor University Medical Center 1286, 1296

Behring Institute 1376

Beijing Tumor Institute 1259

Beijing University 1411

Beki Diagnostics 1252

Ben Venue 1335

Bennet, Turner & Coleman 1404

Berlex Biosciences 1369

Berlex 1411, 1416

Bigmar 1440

BioChem Pharma 1337

BioFocus 1397

Biogen 1413

Biolyse Pharma 1440

bioMerieux-Pierre Fabre 1459

Biomoda 1251

Bion Diagnostic Sciences 1252, 1257

Bioniche Therapeutics 1393

BioNumerik Pharmaceuticals1394, 1430, 1434, 1435, 1478

Bio-Technology General (BTG) 1394, 1435

Boston BioSystems 1290, 1313

Boston Medical Center 1259

Boston University 1374

Brady Urological Institute 1324, 1377

Bristol-Myers Squibb (BMS)1299, 1300, 1301,

1326, 1332, 1410, 1412, 1413, 1430,1431, 1432, 1436, 1437, 1438, 1439, 1440, 1441, 1451, 1454, 1478, 1479

British Biotech 1480

British Columbia Cancer Agency1284, 1300, 1302, 1303, 1306, 1428

British Columbia Cancer Center 1472

I N D E X O F C O M P A N I E S & I N S T I T U T I O N S

6

FUTURE ONCOLOGY VOLUME 6, NUMBER 1-12 INDEX JUNE 2002

COPYRIGHT © 2002 NEW MEDICINE INC. 949. 830. 0448.

British Technology Group (BTG) 1410

Brown University 1369

Bryn Mawr College 1438

Burham Institute 1315

C. R. Bard 1257

Calydon 1377, 1379, 1394, 1401

Canadian Genetic Diseases Network 1290

Cancer Institute (Japan) 1382

Cancer Institute of New Jersey 1417

Cancer Research Campaign (CRC) 1389, 1394

Cancer Research Campaign (UK) 1444

Cancer Research Campaign Institute 1252, 1264

Cancer Research CampaignTechnology (CRCT) 1412

Cancer Research Ventures 1480

Cancer Therapy Research Center(San Antonio, TX) 1302

CancerCare Manitoba 1306

Canji 1341, 1342, 1343, 1370, 1378, 1394, 1402, 1414, 1430

Celgene 1413, 1431

Cell Genesys 1342, 1370, 1401, 1415, 1417, 1479

Cell Pathways1395, 1400, 1431, 1470

Cell Therapeutics (CTI) 1326, 1386, 1411, 1437, 1441, 1443, 1445

Celltech Group 1430

Celltech Medeva 1335

Center for Biologics Evaluation and Research 1481

Centre Alexis Vautrin (France) 1325

Centre Antoine Lacassagne (France) 1464

Centre Jean Perrin (France) 1466

Centre Oscar Lambret (France) 1459

Centre Rene Gauducheau (France) 1453

Centro di Riferimento Oncologico (Italy) 1469

Centro Medico Nacional Siglo XXI IMSS (Mexico) 1469

Chiba Cancer Center ResearchInstitute (Japan) 1372, 1407, 1418

Chiba University School of Medicine (Japan) 1372, 1407

Children’s Hospital at HarvardMedical School 1431, 1479

Children’s Hospital of Boston 1370

Chiron 1294, 1295, 1305, 1318, 1343, 1413, 1433, 1478

ChromaVision Medical Systems 1251

Chugai Biopharmaceuticals 1316

Chugai Institute for MolecularMedicine 1317

Chugai Pharmaceutical1316, 1317, 1397, 1410, 1436, 1445

Ciphergen Biosystems 1250, 1252

CIS Biointernational 1416

City Hospital (UK) 1402

City of Hope National Medical Center 1272

Clayton Foundation for Research 1447

Cleveland Clinic Cancer Center 1450

Cleveland Clinic Foundation1254, 1259, 1291, 1305, 1315

Clinica Universitaria (Spain)1463, 1466, 1467

Codon Pharmaceuticals 1270

Coley Pharmaceutical Group (CPG) 1290, 1291, 1312, 1314, 1315

Collgard Biopharmaceuticals1389, 1395

Columbia University1291, 1367, 1395, 1461

Competitive Technologies1295, 1318, 1433

CoPharma 1413

Corixa 1367, 1392

Cornell University 1441

Covance Biotechnology Services 1479

CRC Technology 1430

Curacel International 1482

Cytoclonal Pharmaceutics (CPI) 1291, 1315

Cytogen 1416

CytoGenix 1274, 1395

Cytran 1431

Dabur India 1440

Daiichi Pharmaceutical1437, 1452, 1479

Dako 1255

Dana-Farber Cancer Institute1414, 1461, 1463

Danish Cancer Society 1290

Dartmouth Medical 1396

Dartmouth-Hitchcock Medical Center 1472

Dendreon 1395

DepoMed 1290, 1314

DiagnoCure 1251, 1253, 1255

Diakonissehjemmets UniversityHospital (Norway) 1351

Diomed 1338, 1411

Dow Chemical 1416

Dr. Reddy’s Laboratories 1479

Drug Royalty 1441

Duke University Medical Center 1395, 1479

Duke University 1292, 1426

Eastern Cooperative OncologyGroup (ECOG) 1287, 1297

Eastern Virginia School of Medicine 1250

Edgardo Rebagliati Hospital (Peru) 1469

Edith Nourse Rogers MemorialVeterans Hospital 1372

Eichrom Technologies 1252, 1261

Elan 1289, 1293, 1317, 1318, 1319, 1396, 1411, 1413, 1473

Eli Lilly 1288, 1326, 1386, 1395, 1396, 1397, 1400, 1412,

1431, 1432, 1457, 1458, 1459, 1479

Emory University 1415

Enchira Biotechnology 1395

EntreMed 1370, 1431, 1479

Enzon 1438, 1448

EORTC 1267

EpiGenesis Pharmaceuticals1279, 1315

Epimmune 1407

Ergo Science 1397

Esteve 1482

European Institute of Oncology (Italy) 1388, 1466

European Molecular BiologyLaboratory (Germany) 1376

European Organization for Research and Treatment of Cancer (EORTC) 1428

eXegenics 1438, 1440

Exiqon 1290

EyeTech Pharmaceuticals 1294

Faulding 1255, 1440, 1441

Feist-Weiller Cancer Center 1263

Ferrer Internacional 1411, 1413

Fisher Diagnostics 1259

Fisher Scientific 1259

Florida State University 1454

Food and Drug Administration (FDA) 1255, 1256, 1258, 1259

Fox Chase-Temple University Cancer Center 1446

Fox-Chase Temple Cancer Center 1287

Freie Universitat Berlin (Germany) 1256, 1266

Fuji Gotemba Laboratories 1317

Fujirebio 1251

Fujisawa Pharmaceutical 1479

Galderma Research & Development 1395

Galena 1436, 1440

Gemini Technologies1291, 1308, 1315

Genaera 1431

Gencell 1402

Genelabs Biotechnologies (GBL) 1445

Genentech 1413, 1424, 1431, 1432, 1433, 1461

General Biologicals 1259

General Hospital Celle 1398

General Hospital of Bolzano (Italy) 1266

GeneSense Technologies1291, 1314, 1317, 1318

Genetic Therapy 1347

Genetics Institute (GI) 1395, 1399, 1416

GeneTrove 1317

Genotherapeutics 1367

Genovate Biotechnology 1438, 1445

Genphar 1342, 1418

GenQuest 1367

Genset Oligos 1313

Genta1291, 1292, 1294, 1300, 1302,

1303, 1304, 1308, 1315, 1395, 1432

GenVec 1344, 1479

Genzyme Molecular Oncology(GMO) 1292,

1346, 1394, 1395, 1408, 1430

GeoMed 1397

George Washington University Medical Center 1338

Georgetown University Medical Center 1438

Georgetown University1287, 1294, 1298, 1303, 1480

Geron 1252, 1261, 1292

Gesellschaft für BiotechnologischeForschung (GBF) 1479

Gilead Sciences 1274, 1275, 1294, 1317, 1318, 1411

Glaxo SmithKline 1290, 1314, 1317

Glaxo Wellcome 1275

GlaxoSmithKline Biologicals 1392, 1397

GlaxoSmithKline1395, 1410, 1411, 1416, 1427, 1431, 1459, 1470, 1479, 1480

GPC Biotech 1313

Gray Laboratory Cancer ResearchTrust (CRT; UK) 1371, 1374, 1381

Grelan Pharmaceutical 1430, 1435

Grupo Ferrer 1338, 1411

GTC Biotherapeutics 1480

Guilford Pharmaceuticals 1438, 1447

7

FUTURE ONCOLOGY VOLUME 6, NUMBER 1-12 INDEX JUNE 2002

COPYRIGHT © 2002 NEW MEDICINE INC. 949. 830. 0448.

Guy’s Hospital (UK) 1445

H. Lee Moffitt Cancer Center and Research Institute 1401

H. Lee Moffitt Cancer Center 1451

Hadassah Medical Center (Israel) 1257

Hadassah-Hebrew UniversityHospital (Israel) 1389

Hallym University College ofMedicine (Korea) 1461

Hammersmith Hospital (UK) 1367

Harvard College 1480

Harvard Gene Therapy Initiative1373, 1381, 1383

Harvard Medical School1370, 1417, 1437

Hebrew University (Israel) 1377, 1382

Helsinki University Central Hospital(Finland) 1465

Henry Ford Health System 1373

Hoechst Celanese 1397, 1433

Hoechst 1376

Hoffmann-La Roche1395, 1410, 1411, 1413,

1416, 1431, 1433, 1460, 1479

Hokkaido University (Japan) 1367, 1383

Hospital de Pulido Valente (Portugal) 1462

Hospital General Universitario de Alicante (Spain) 1265

Hospital Universitario Doce deOctubre (Spain) 1471

Hospital University of San Carlos (Spain) 1463

Hospital Vall d’Hebron (Spain) 1453

Hotel-Dieu de France Hospital(Lebanon) 1463

Human Gene Therapy Research Institute 1367, 1371, 1372

Humbobolt-Universitat zu Berlin 1271, 1292

Humboldt University (Germany) 1379

Hybridon Specialty Products 1313

Hybridon 1292, 1298, 1308, 1316, 1318, 1432

Hybritech 1259

IAF BioVac 1337

Ibis Therapeutics 1317

ICIG (France) 1466

IDEC Pharmaceuticals1413, 1474, 1480

IDL Biotech 1251, 1265

IGT 1473

Ilex Oncology1387, 1395, 1479, 1480

Illumina 1313

ImClone Systems 1395, 1432

Immunex 1334, 1396, 1412, 1416, 1430, 1441

Immuno-Designed Molecules (IDM) 1393, 1396

ImmunoGen 1413, 1431, 1432, 1438, 1454, 1480

Immunomedics 1396

Immusol 1292, 1309, 1316

Imperial College School of Medicine at St. Mary’s (UK) 1346

Indena1437, 1438, 1440, 1448, 1450, 1478

Indiana University 1288

Inex Pharmaceuticals 1284, 1285, 1292, 1293, 1307, 1317, 1473, 1474

Ingenex 1396

Innovir Laboratories 1318

INSERM (France) 1369, 1466

Institut Curie (France) 1376

Institut Gustave Roussy (France) 1342, 1468

Institut Pasteur (France) 1337

Institute of Cancer Research (UK) 1287, 1303, 1410

Instituto Valenciano de Oncologia (Spain) 1334

Interpharma-Praha 1480

Intracel 1252, 1393, 1396, 1397

Intraop Medical 1388

Introgen Therapeutics1293, 1342, 1365, 1366,

1367, 1371, 1380, 1396, 1401

Ireland Cancer Center 1304

Isis Pharmaceuticals 1282, 1286, 1287,

1289, 1290, 1291, 1293, 1294, 1296, 1314, 1317, 1396, 1432, 1480

Istituto Nazionale per lo Studio e la Cura dei Tumori (Italy) 1471

Ivax 1410, 1436, 1438, 1439, 1440, 1441, 1447, 1448, 1480

James Graham Brown Cancer Center 1380

Janssen Biotech 1439

Janssen Cilag 1416

Janssen Pharmaceutica1396, 1400, 1432

Janssen-Cilag 1428, 1432

Japan Tobacco 1396

JCR Pharmaceuticals 1441

Jewish General Hospital (Canada) 1284

Johannes Gutenberg University(Germany) 1366

Johns Hopkins Hospital Oncology Center 1377

Johns Hopkins University1292, 1306,

1315, 1324, 1438, 1447, 1449, 1450

Johnson & Johnson1317, 1388, 1404, 1416

Jonsson Comprehensive Cancer Center 1471, 1474

Josai University 1269

Kagoshima University (Japan) 1372

Karmanos Cancer Center 1452

Karolinska Hospital (Sweden) 1368

Karolinska Institute 1290, 1451

Kennedy Krieger Research Institute 1294

KI Pharma 1435

Kimeragen 1273

Kimmel Cancer Center 1286, 1307

King’s College London 1345, 1414

Kitasato University School of Medicine (Japan) 1383

Konica 1259

Koo Foundation Sun Yat-Sen Cancer Center (Taiwan) 1445

Kosan Biosciences 1480

Krankenhaus Grosshansdorf(Germany) 1467

KS Biomedix 1396

KuDOS Pharmaceuticals 1480

Kyowa Hakko Kogyo1292, 1396, 1432, 1459

La Jolla Cancer ResearchFoundation 1315

Lachema 1439

Larova Biochemie 1313

LeukoSite 1396

Lexon 1252

Ligand Pharmaceuticals1396, 1411, 1413

Loma Linda University School of Medicine 1345, 1414

Loma Linda University 1381

Lombardi Cancer Center 1298

Lorus Therapeutics1290, 1306, 1314, 1317, 1318

Louisiana State University Health Sciences Center 1263

Louisiana State University1292, 1308, 1309

Loyola University Medical Center 1336

Ludwig Institute for Cancer Research 1290, 1291,

1314, 1316, 1392, 1395, 1397

Lynx Therapeutics1285, 1292, 1293, 1317

M. D. Anderson Cancer Center1250, 1259, 1293, 1295, 1305, 1308, 1338, 1342, 1365, 1376,1378, 1380, 1383, 1388, 1394,

1396, 1402, 1407, 1433, 1437, 1439, 1442, 1443, 1444, 1473, 1474, 1475

Mackay Memorial Hospital (Taiwan) 1445

MacroMed 1438, 1442, 1446

MainGen Biotechnologie 1376

Manitoba Cancer Treatment and Research Foundation 1317

Martek Biosciences 1438

Massachusetts General Hospital 1259, 1275

Massachusetts Institute ofTechnology (MIT) 1252, 1259, 1438

Matritech 1252, 1258, 1259

Mayne Group 1440

Mayne Nickless 1440

Mayo Clinic 1288, 1377, 1387, 1434

Mayo Graduate School of Medicine 1254

McGill University 1429

MDS Capital 1441

MDS Research Foundation 1454

Medarex 1393, 1396

Medical College of Wisconsin 1372

Medical Research Council (MRC) 1235, 1397

Medical School Mainz (Germany) 1324

Medical University of Gdansk(Poland) 1460

Medical University of South Carolina 1294, 1342, 1418

Medimmune 1417

MedImmune 1444

Medizyme Pharmaceuticals1294, 1319

Memorial Sloan-Kettering Cancer Center (MSKCC)

1302, 1323, 1326, 1333, 1411, 1424, 1444, 1445, 1480

Mentor 1252, 1261, 1396, 1398

Merck KGaA1256, 1395, 1396, 1432, 1480

MethylGene 1294, 1305, 1306, 1318

MGI Pharma 1294, 1306, 1318

Miguel Labs 1410

Millennium Pharmaceuticals 1396, 1400, 1451

Millennium Predictive Medicine 1451

ML Laboratories 1342, 1430

Mojave Therapeutics 1480

Molecular Biosystems1291, 1292, 1315, 1395, 1432

8

FUTURE ONCOLOGY VOLUME 6, NUMBER 1-12 INDEX JUNE 2002

COPYRIGHT © 2002 NEW MEDICINE INC. 949. 830. 0448.

Monsanto 1316

Montefiore Medical Center 1299

Mount Vernon Hospital (UK) 1325, 1371

MPI Research 1395

Municipal University Hospital 1403

MWG-Biotech 1313

Myelos 1435

Mylan Pharmaceuticals 1441

NABTT CNS Consortium 1297

Nagoya University School of Medicine (Japan) 1372

NaPro BioTherapeutics 1440, 1441

Nara Medical University (Japan) 1462

National Cancer Center Hospital East (Japan) 1468

National Cancer Center Research Institute (Japan) 1462

National Cancer Hospital (Japan) 1453

National Cancer Institute (Italy) 1388

National Cancer Institute (NCI) 1270, 1291,

1294, 1295, 1303, 1304, 1312, 1315, 1337, 1363, 1387, 1388, 1395, 1396, 1397, 1411, 1428, 1430, 1431, 1432, 1433, 1462, 1472, 1478, 1481

National Cancer Institute of Canada 1286, 1297

National Hospital (South Africa) 1470

National Human Genome Research Institute (NHGRI) 1263

National Institute of Allergy andInfectious Diseases (NIAID) 1315

National Institutes of Health (NIH) 1263, 1291, 1295,

1315, 1382, 1397, 1433, 1480

National Research Institute forRadiotherapy and Radiohygiene(Hungary) 1382

Natural Pharmaceuticals 1441, 1445

NDDO Oncology 1392, 1397, 1478

NeoOncoRx 1397

NeoPharm 1287, 1294, 1438, 1445, 1446, 1480, 1481

NeoRx 1481

New York University School of Medicine 1341

Nexagen 1275

Nexell Therapeutics 1318

NeXstar Pharmaceuticals1275, 1294, 1313

Niigata University School of Medicine 1397

Nippon Kayaku 1412

Nippon Roche 1410

Nobex 1438

Nordic Drugs 1439

Norfolk and Norwich UniversityHospital (UK) 1474

North Central Cancer TreatmentGroup (NCCTG) 1288

Northwest Biotherapeutics 1481

Northwestern University School of Medicine 1372

Norwegian Radium Hospital (NRH) 1403

Norwegian Radium HospitalResearch Foundation 1403

Novartis Horsham Research Centre 1279

Novartis Pharmaceuticals1293, 1294, 1317, 1404,

1416, 1417, 1427, 1471, 1481

Novation 1441

Novocastra Laboratories 1263

NS Pharma 1481

Oasis Biosciences 1315

Ohio State University 1304

Okayama University Medical School 1390

Oncology Institute (Italy) 1469

Oncor 1270

Oncormed 1396

Oncotech 1426

Ontario Cancer Institute 1344, 1366

Ontogen 1428, 1433

Onyx Pharmaceuticals1342, 1343, 1366, 1378, 1433, 1478

OraSense 1289, 1317

Organon 1337

Organon Teknika 1337

Orion Pharma 1412

Ortho Biotech 1416

Osaka City University Medical School (Japan) 1408, 1409

OSI Pharmaceuticals1397, 1433, 1481

Ospedale di Circolo Fondazione Macchi (Italy) 1337

Ospedali Riuniti di Bergamo (Italy) 1334

Ottawa Regional Cancer Centre 1306

Oxford BioMedica 1481

Paladin Labs1257, 1335, 1337, 1395, 1431

Palo Alto VA GenitourinaryOncology Clinic 1386

Pangene 1382

Parke-Davis 1433

Paterson Institute for CancerResearch 1480

Pennsylvania State UniversityCollege of Medicine 1409

PerImmune 1261

Pfizer Global Research andDevelopment 1433, 1481

Pfizer 1342, 1343, 1366, 1378, 1397, 1433, 1481

Pharmacia 1304, 1326, 1374, 1391,1397, 1411, 1438, 1445, 1446, 1480

Pharmacyclics1272, 1294, 1397, 1433

Pharma-Eco 1290

PharmaGenix 1274

PharmaMar 1481, 1482

Pharmion 1431

Pharsight 1396

Phillips Petroleun 1253

Phogen 1313

PhotoCure 1397, 1402

Physician Reliance Network(PRN) 1288, 1296

Phytogen Life Sciences 1438, 1441

Phyton 1441

Pierre Fabre Médicaments1459, 1475

Pierre Fabre 1410

Polska Akademia Nauk 1292, 1315

PolyMASC Pharmaceuticals 1433

Polymedco 1252, 1257

Polymer Laboratories 1478

Prescient NeuroPharma 1473, 1482

Princess Margaret Hospital (Canada) 1306

Professional Compounding Centers of America 1274

Prolifix 1397

Proligo 1291, 1313, 1318

ProlX Pharmaceuticals 1482

Protarga 1438, 1449, 1450

Protein Design Labs (PDL) 1413,1431

Pulido Valente (Portugal) 1462

QLT 1338, 1411, 1429, 1472

Queen’s University 1399

R.W. Johnson PharmaceuticalResearch Institute (PRI) 1317

Regina Elena Cancer Institute 1285, 1292, 1293

Research Corporation Technologies (RCT) 1416

Ribozyme Pharmaceuticals (RPI) 1271, 1294, 1295,

1305, 1313, 1318, 1319, 1433

Robert Wood Johnson (RWJ) Medical School 1269

Roberts Pharmaceutical 1388

Roche Diagnostics1250, 1251, 1252, 1264, 1395

Roche Laboratories 1431

Rockefeller University 1275

Roswell Park Cancer Institute 1337,1428, 1437, 1450, 1472, 1474, 1478

Rotterdam Cancer Institute (The Netherlands) 1446

Rowland Institute for Science 1397

Royal Marsden Hospital (UK) 1293, 1450

Royal Surrey County Hospital (UK) 1429

Royalty Pharma 1431

RPR Gencell 1402

Sam Waxman Cancer Research Foundation 1411

Samyang Genex 1438, 1442

San Antonio Cancer Institute 1304

Sangtec 1251

Sankyo 1387, 1416

Sanofi-Synthelabo 1326, 1410, 1462

Sapporo Medical College (Japan) 1407

Sarah Cannon Cancer Center 1448

Schering AG 1275, 1411

Schering-Plough Research Institute 1342, 1370

Schering-Plough1337, 1365, 1397, 1402,

1407, 1411, 1412, 1413, 1417, 1433

Scotia Pharmaceuticals 1391, 1397

Searle 1292, 1316

Seinajoki Central Hospital (Finland) 1257

Selective Genetics 1347, 1396

Seoul National University College of Medicine (Korea) 1367

Sequitur 1315

Shinshu University School ofMedicine (Japan) 1347

Shire BioChem 1429, 1434

Shire Pharmaceuticals Group 1388, 1412

Sidney Kimmel Cancer Center1340, 1341, 1364, 1396, 1406

Sigma-Tau 1482

Sinphar Pharmaceutical 1441

Situs 1335

SKW Trotsberg 1318

Solbec Pharmaceuticals 1482

Somagenics 1295

Sonus Pharmaceuticals 1438, 1448

Southampton General Hospital (UK) 1391

Southern Arizona VA HealthCare System 1475

Sperling Sampson West 1411

SRI International 1388

St. James’ Hospital (Ireland) 1373

9

FUTURE ONCOLOGY VOLUME 6, NUMBER 1-12 INDEX JUNE 2002

COPYRIGHT © 2002 NEW MEDICINE INC. 949. 830. 0448.

St. Jude Children’s Research Hospital 1375

St. Louis University School of Medicine 1343

St. Luke’s Hospital (Ireland) 1373

St. Savas Hospital (Greece) 1465

Stanford University Medical Center 1289, 1296

Stanford University 1326, 1275,1386, 1425, 1451, 1480, 1481

State University of New York (SUNY) at Stony Brook

1428, 1437, 1438, 1441, 1450, 1454, 1478

STS Particles 1438

Sugen 1482

Sumitomo Pharmaceuticals1389, 1397

SuperGen 1412, 1439, 1447

Supratek Pharma1346, 1408, 1439, 1449

Swiss Federal Institute of Technology 1403

Syncure 1454

Taiho Pharmaceutical 1410, 1482

Takeda Chemical Industries 1480

Takeda Group 1435

Tampere University Hospital(Finland) 1257

Tangerine Technologies 1313

TAP Pharmaceutical Products 1433

TAP Pharmaceuticals 1413

Targeted Genetics 1433

Tata Memorial Hospital (India) 1469

Taussig Cancer Center 1305

Taxolog 1439, 1454

Teikoku Hormone 1482

Teikyo University School of Medicine (Japan) 1347

Tel Aviv University 1295, 1397

Tetrionics 1431

Theradex 1450

Thomas Jefferson University 1272,1273, 1286, 1295, 1307, 1345, 1417

Titan Pharmaceuticals 1397

Tokai University School of Medicine (Japan) 1369

Tokyo Medical and Dental University (Japan) 1368

Transgene 1379, 1394, 1415, 1430

Transgenics Berlin-Buch 1313

Transkaryotic Therapies (TKT) 1370

TranXenoGen 1396

Trinity College 1480

Tularik 1482

Tzamal Pharma 1441

UCSF Cancer Center and Cancer Research Institute 1401

United States Biochemical 1318

Universitá Federico II (Italy) 1298

Université de Montreal 1272

University College of London 1290

University Hospital Nijmegen (The Netherlands) 1251

University Medical Center Nijmegen (The Netherlands)

1255, 1256

University Medical Center of Utrecht (The Netherlands) 1300

University of Alabama atBirmingham (UAB)

1292, 1295, 1308, 1316, 1372

University of Alabama atBirmingham 1400

University of Alabama 1277

University of Arizona 1344

University of Bari-Urology Clinic (Italy) 1469

University of Basel (Switzerland) 1263

University of Bergen (Norway) 1347, 1370

University of British Columbia1300, 1473, 1482

University of Calgary 1345

University of California at San Diego 1375

University of California at San Francisco 1365

University of California Davis 1427

University of California Los Angeles (UCLA) 1474

University of California San Diego 1395, 1408, 1432

University of California San Francisco (UCSF) 1474

University of California Santa Barbara 1425

University of California 1264, 1292

University of California, Irvine 1418

University of California, Los Angeles 1406

University of Cambridge 1264

University of Chicago Medical Center 1286, 1296, 1303, 1306

University of Cincinnati Medical Center 1445

University of Colorado Cancer Center 1409

University of Colorado1270, 1292, 1294, 1295, 1318, 1433

University of Copenhagen 1290

University of Delaware 1273

University of Essen 1447

University of Florida 1295

University of Frankfurt MedicalSchool (Germany) 1376

University of Hawaii 1481

University of Illinois1337, 1406, 1407

University of Iowa1290, 1291, 1312, 1314, 1431

University of Kentucky 1414

University of L’ Aquila 1290

University of Leeds (UK) 1474

University of London (UK) 1478

University of Louisville 1380

University of Manitoba 1291, 1317

University of Massachusetts1272, 1278, 1295, 1397

University of Medicine and Dentistry of New Jersey (UMDNJ) 1269

University of Miami School of Medicine 1266

University of Michigan 1275

University of Montreal 1337

University of Muenster (Germany) 1379

University of Naples (Italy) 1292, 1309

University of Nebraska 1290, 1314

University of North Carolina1292, 1373

University of Orleans (France) 1346

University of Palermo (Italy) 1470

University of Pennsylvania1285, 1287, 1291, 1315

University of Pennsylvania1395, 1407, 1432, 1451

University of Pittsburgh Medical School 1373, 1407

University of Pittsburgh1252, 1260, 1433, 1452

University of Pretoria (South Africa) 1470

University of Southern California (USC) 1347, 1370

University of Tennessee 1367

University of Texas at Austin 1272

University of Texas SouthwesternMedical Center (UTSW) 1292

University of Texas 1291, 1293, 1294, 1295, 1315, 1342, 1365, 1394, 1395, 1396, 1397, 1402, 1433, 1437, 1439, 1442, 1443, 1474, 1475

University of Tokyo (Japan) 1375

University of Toronto 1344

University of Tromso (Norway) 1368

University of Tsukuba (Japan) 1271, 1295

University of Ulsan College of Medicine (Korea) 1373, 1382

University of Ulsan College of Medicine (Korea) 1464

University of Verona (Verona, Italy) 1466

University of Vienna1255, 1301, 1304

University of Virginia HealthSciences Center 1268

University of WisconsinComprehensive Cancer Center 1387

University of Wisconsin 1470

University of Yonsei College of Medicine (Korea) 1373

University Research Corporation 1318

UroCor1252, 1337, 1363, 1394, 1399

US Oncology 1367, 1437, 1444

VA Medical Center-Long Beach 1418

Valentis 1346, 1409, 1414

ValiGen 1273, 1295

Vanderbilt University Medical Center 1344

Variagenics 1481

Varian Medical Systems 1479

Velindre Hospital 1389

Vertex Pharmaceuticals 1429, 1434

Veterans General Hospital-Taipei (Taiwan) 1445

Vical 1346, 1409

Vienna General Hospital (Austria) 1467

Vion Pharmaceuticals 1434

Vysis 1252, 1263

Wayne State University School of Medicine 1324

Wayne State University 1452

Weiler Hospital 1299

Weizmann Institute of Science 1394

West Virginia University School of Medicine 1398

West Virginia University 1338

Western University of Ontario 1457

Wyeth-Ayerst Pharmaceuticals1395, 1399, 1439, 1454

Xechem International 1439, 1442

Xenova 1472

Xenova Group 1429

Xoma 1433, 1482

Yale University School of Medicine 1343, 1395

Yale University1264, 1270, 1275, 1295, 1382, 1434

YM BioSciences 1396

Yokohama City University (Japan) 1375

Yokult Honsha 1391, 1410

Zeneca Specialties 1313

Zenyaku Kogyo 1413

Zycos 1397

10

FUTURE ONCOLOGY VOLUME 6, NUMBER 1-12 INDEX JUNE 2002

COPYRIGHT © 2002 NEW MEDICINE INC. 949. 830. 0448.

11

FUTURE ONCOLOGY VOLUME 6, NUMBER 1-12 INDEX JUNE 2002

COPYRIGHT © 2002 NEW MEDICINE INC. 949. 830. 0448.

A NEW MEDICINE PUBLICATION VOLUME 6, NUMBER 1-12 INDEX JUNE 2002

COPYRIGHT © 2002 NEW MEDICINE INC. 949. 830. 0448

FUTURE ONCOLOGY:FUTURE ONCOLOGY (ISSN 1082-331X) is published as 12 issues(several double issues) per year, with a free annual indexlisting companies/institutions and subjects covered, and abinder.

❑ YES, I want to order a subscription to FUTURE ONCOLOGY.

Subscription Information:

❑ One-year subscription is $840 U.S. and $900 abroad;please specify period (from _______ to _______ ). Additionalsubscriptions sent in the same envelope are $390 each.

Back Issues:

❑ Volumes V2, V3, V4, and V5 are $2,400 (U.S.) and $2,460(outside the U.S.).

❑ Volumes V4 and V5 are $1,400 (U.S.) and $1,460 (outsidethe U.S.).

Inquiry Information:

❑ Please send me a sample issue of FUTURE ONCOLOGY

❑ Please send me the index of Volumes 1, 2, 3, 4 and 5

Oncology Knowledgebase ( ):

❑ YES, I want to order a order .

is available by subscription only and access is pro-vided via a password. The annual subscription rate is$2,950 for the first “seat” and $290.00 for each additional seat for up to 5 seats in the same physical loca-tion. Subscription rates for company-wide distribution arenegotiable, based on physical location/IP designation andnumber, of users.

Please enter my subscription to to start on

(date) __________________________ at $2,950.00 ____________

Additional seats # ____________ at $290.00 each __________

Total ___________

Inquiry Information:

❑ Please call me for a walk-through the database and a complimentary pass.

Sale of NEW MEDICINE hard copy and electronicpublications is made under the following conditions:

Unauthorized photcopying, distribution or electronic storage isstrickly prohibited. Information incorporated in NEW MEDICINE

products is developed from various sources believed to be reli-able. There can be no assurance that such information is accu-rate in all respects, however, and the publisher cannot be heldliable for errors. Errors, when discovered, will be corrected,Subsriptions may not be canceled, but may be transferred.

All orders must be repaid or accompanied by a signed order formor P.O. #. Subscriptions to FUTURE ONCOLOGY and will begin upon receipt of payment. Products are nonreturn-able; please, feel free to call for information.

My check for $ _________ is enclosed (make checks payableto NEW MEDICINE, INC.). Payment must accompany yourorder; checks must be drawn on a U.S. bank

Wire Transfer:

Washington Mutual, 400 East Main Street. Stockton, CA 95290. 800-374-4646. Routing #321180748.NEW MEDICINE INC. Account #087900008012618

Credit Card: ❑ Visa ❑ AmEx ❑ M/C Exp. Date: ______

Bill me on P.O. #: ____________________________________________________

Signature: ____________________________________________________________

Name: ________________________________________________________________

Title: ____________________________ Company: ______________________

Address: ______________________________________________________________

City: ____________________________ State: ____________________________

Zip Code: ______________________ Country: ________________________

Telephone: ______________________ Fax: ____________________________

E-mail ________________________________________________________________

Return to: NEW MEDICINE, INC.:

P.O. Box 909 • Lake Forest • CA 92630Telephone: (949) 830-0448 • Fax: (949) 830-0887E-mail: info@newmedinc.comWeb Sites: www: newmedinc.com

www.oncologyknowledgebase.com

FUTURE ONCOLOGY Staff:

PUBLISHER AND EDITOR: Katie Siafaca, MS

VICE PRESIDENT-OPERATIONS: Beth Schweitzer

ASSISTANT EDITOR: Eugene Delacruz

ASSISTANT EDITOR: Adele Simon

CIRCULATION: Amish Kalyani

DESIGN & PRODUCTION: Jill Burch

EDITORIAL BOARD

BIOTECHNOLOGY & APPLIED SCIENCES:James W. Hawkins, PhD, Editor, Antisense Research and Development

CLINICAL PRACTICE:Leonard Sender, MD, Medical Director, Hemtopoietic Stem Cell Program, St. Joseph Hospital Regional Center, Orange, CA

REIMBURSEMENT AND MANAGED CARE:Elan Rubinstein, PharmD, MPH, Consultant

O R D E R I N G & I N Q U I R Y I N F O R M A T I O N